RxDoctor Payments Data

Karen Dasilva, MD

Neurology · Santa Barbara, CANPI 1831366046

Payments from drug & device makers

$7,895in general payments, 2019–2025

Across 385 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$622
  • Novartis$595
  • EDW Pharma, Inc.$498
  • AstraZeneca$487
  • Pfizer$365
  • plus $4K from 38 others

What the payments were for

  • Speaking & faculty fees$691%
  • Food & beverage$7,81399%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,895 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$69,133
Medicare patients
181
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5062$763,386
OctagamImmun Globg(Igg)/Malt/Iga Ov5027$581,421
Radicava OrsEdaravone29$415,493
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$118,339
Nurtec OdtRimegepant Sulfate14$23,962
UbrelvyUbrogepant12$20,907
Aimovig AutoinjectorErenumab-Aooe13$10,120
Memantine Hcl52$2,131
Riluzole20$1,854
Pyridostigmine Bromide22$1,200
Lidocaine11$942
Sodium Chloride0.9 % Sodium Chloride45$878
Levetiracetam26$874
Pregabalin64$841
Gabapentin56$751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$111$763,38662 claims
PfizerOctagam, Nurtec Odt$365$605,38341 claims
Grifols USA, LLCGamunex-C$82$118,33924 claims
AbbVieUbrelvy$1,483$20,90712 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$24$1,20022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →